Precigen, Inc. (PGEN)
4.52
-0.14
(-3.00%)
USD |
NASDAQ |
Nov 13, 16:00
4.52
0.00 (0.00%)
After-Hours: 19:59
Precigen Net Income (Quarterly) : 35.77M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 35.77M |
| June 30, 2026 | 20.07M |
| March 31, 2026 | -7.929M |
| December 31, 2025 | -23.50M |
| September 30, 2025 | -146.34M |
| June 30, 2025 | -26.64M |
| March 31, 2025 | -54.15M |
| December 31, 2024 | -19.73M |
| September 30, 2024 | -23.98M |
| June 30, 2024 | -58.79M |
| March 31, 2024 | -23.74M |
| December 31, 2023 | -33.06M |
| September 30, 2023 | -19.80M |
| June 30, 2023 | -20.32M |
| March 31, 2023 | -22.73M |
| December 31, 2022 | -22.18M |
| September 30, 2022 | -7.644M |
| June 30, 2022 | -26.06M |
| March 31, 2022 | -23.90M |
| December 31, 2021 | -26.70M |
| September 30, 2021 | -26.32M |
| June 30, 2021 | -30.94M |
| March 31, 2021 | -21.84M |
| December 31, 2020 | -0.969M |
| September 30, 2020 | -27.54M |
| Date | Value |
|---|---|
| June 30, 2020 | -15.71M |
| March 31, 2020 | -20.85M |
| December 31, 2019 | -36.08M |
| September 30, 2019 | -49.05M |
| June 30, 2019 | -32.30M |
| March 31, 2019 | -52.90M |
| December 31, 2018 | -274.59M |
| September 30, 2018 | -58.75M |
| June 30, 2018 | -66.83M |
| March 31, 2018 | -43.23M |
| December 31, 2017 | -33.94M |
| September 30, 2017 | -40.84M |
| June 30, 2017 | -19.66M |
| March 31, 2017 | -32.38M |
| December 31, 2016 | -44.91M |
| September 30, 2016 | -30.01M |
| June 30, 2016 | -50.03M |
| March 31, 2016 | -65.32M |
| December 31, 2015 | -33.28M |
| September 30, 2015 | -39.03M |
| June 30, 2015 | -41.49M |
| March 31, 2015 | 25.80M |
| December 31, 2014 | 17.93M |
| September 30, 2014 | -53.86M |
| June 30, 2014 | -52.94M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | -0.311M |
| Aldeyra Therapeutics, Inc. | -3.763M |
| Repligen Corp. | -38.43M |
| AC Immune SA | -10.77M |
| Inovio Pharmaceuticals, Inc. | -49.20M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 74.15M |
| Total Expenses (Quarterly) | 38.38M |
| EPS Diluted (Quarterly) | 0.0849 |
| Enterprise Value | 1.723B |
| Gross Profit Margin (Quarterly) | 90.79% |
| Profit Margin (Quarterly) | 48.24% |
| Earnings Yield | 0.99% |
| Operating Earnings Yield | 1.93% |
| Normalized Earnings Yield | 0.9867 |